Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adma Biologics (NQ: ADMA )

16.54 -0.61 (-3.56%)
Streaming Delayed Price Updated: 10:26 AM EDT, Oct 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Adma Biologics

< Previous 1 2 3 4 5 Next >
Key Takeaways From ADMA Biologics Analyst Ratings
Via Benzinga
CVS Has 'Real Value,' Jim Cramer Says: Micron Had An 'Amazing' Quarter
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
This Is What Whales Are Betting On ADMA Biologics
Via Benzinga
IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns
The company reiterated its outlook for 2024 and 2025. 
Via Investor's Business Daily
Exploring high growth characteristics of ADMA BIOLOGICS INC (NASDAQ:ADMA).
Why ADMA BIOLOGICS INC (NASDAQ:ADMA) qualifies as a high growth stock. 
Via Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:ADMA.
Looking for growth without the hefty price tag? Consider NASDAQ:ADMA. 
Via Chartmill
In-Depth Examination Of 4 Analyst Recommendations For ADMA Biologics
Via Benzinga
Assessing ADMA Biologics: Insights From 4 Financial Analysts
Via Benzinga
What's Going On With ADMA Biologics Stock Monday?
ADMA Biologics shares are moving higher after it was announced that the company will join the S&P SmallCap 600. 
Via Benzinga
Topics Stocks
Exposures US Equities
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
Via Benzinga
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86. 
Via Investor's Business Daily
'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics
"Mad Money" host Jim Cramer said, "Any time there's immunity-compromised patients, there's some big money down the road." 
Via Benzinga
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers. 
Via Investor's Business Daily
Biohaven Stock Earns Relative Strength Rating Upgrade
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91. 
Via Investor's Business Daily
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance. 
Via Investor's Business Daily
Immunome Stock Sees RS Rating Jump To 91
Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91. 
Via Investor's Business Daily
PTC Therapeutics Stock Earns RS Rating Upgrade To 83
The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Lumen, Upstart, ADMA, Sweetgreen, Veracyte, Clear Secure, and Core Scientific were best performers last week. Did you invest in them? 
Via Benzinga
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
Via Benzinga
ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q2 2024
ADMA stock results show that ADMA Biologics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82. 
Via Investor's Business Daily
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier. 
Via Investor's Business Daily
Beam Therapeutics Stock Earns RS Rating Jump To 85
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85. 
Via Investor's Business Daily
Jim Cramer Recommends Not Selling Vertiv, Says Buy This Social Media Stock 'Hand Over Fist'
Mad Money's Jim Cramer recommends holding on to Vertiv Holdings, which is set to report its Q2 results before the opening bell on July 24. 
Via Benzinga
Leslie's Issues Preliminary Financial Results, Joins Beyond Meat, Domino's And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Biotech Arvinas Stock Earns 82 RS Rating
The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82. 
Via Investor's Business Daily
Denali Therapeutics Stock Gets Technical Rating Upgrade
Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
3 Millionaire-Making Stock Picks With Astounding Growth Potential
Owning millionaire-making stocks can be a life changer. Look no further than these three companies which are full of potential. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.